Overview
A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)
Status:
Completed
Completed
Trial end date:
2014-01-01
2014-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will compare the plasma pharmacokinetics of a single 125mg oral dose of palbociclib in the presence and absence of rifampin-mediated enzyme induction in a fixed-sequence two-period study.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
PfizerTreatments:
Palbociclib
Rifampin
Criteria
Inclusion Criteria:- Healthy males or females of non-childbearing potential
- body mass index between 17.5-30.5 kg/m2 with a total body weight greater than 50kg
Exclusion Criteria:
- Evidence or history of any clinically significant physiologic, psychological, or
medical conditions
- a positive drug screen or alcohol breath test
- a baseline ECG demonstrating a QTc>450msecs or a QRS interval >120msecs